A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

Summary

In this open-label study, eligible and consenting adult patients admitted to the hospital for critical care that have acute severe anemia, defined as a blood hemoglobin level ≤ 5 g/dL, but who are unwilling or unable to receive red blood cell (RBC) transfusion, will receive one or more infusions of SANGUINATE as are deemed necessary by the Investigator for survival of the acute anemic episode.

Timeline

Start

2016-03

Primary completion

2017-05-17

Completion

2017-05-17

Drugs

Indications